REVIEW article
Front. Oncol.
Sec. Pediatric Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1520171
This article is part of the Research TopicImmunological Therapies in Pediatric Cancers: A Latin American PerspectiveView all 4 articles
High-Risk Neuroblastoma in Mexico: From Multimodal Treatment to Immunotherapy. Regarding the first case treated with Naxitamab
Provisionally accepted
Alberto Olaya Vargas1*
Haydee Salazar-Rosales1Marcela Caballero-Palacios2Nideshda Ramírez-Uribe3Gerardo López-Hernández3Erika Morales-Martinez3
María Cervantes-Delgado3
Liliana Velasco Hidalgo2Araceli Castellanos-Toledo2Rocío Cárdenas-Cardos2,4Ana Niembro-Zúñiga2
Roberto Rivera-Luna2
Alberto Olaya-Nieto3
Jesús Ponce-Cruz4
Jaime Shalkow4
Yadira Melchor-Vidal4
Rodrigo Díaz-Machorro4- 1Department of Hematopoietic Transplantation and Cellular Therapy, National Institute of Pediatrics (Mexico), Mexico City, Mexico
- 2Oncology Service of the National Institute of Pediatrics., Mexico City, Mexico
- 3Instituto Nacional de Pediatria. Department of Hematopoietic Transplantation and Cellular Therapy, Mexico City, Mexico
- 4Pediatric Hemato-Oncology Unit, ABC Medical Center, Mexico City, Mexico
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The primary objective of implementing novel immunotherapeutic strategies, in addition to improving event-free survival (EFS) and overall survival (OS) in patients diagnosed with high-risk neuroblastoma, is to reduce adverse effects and lower both short-and long-term mortality. It is worth noting that the current cost of anti-GD2 therapies available in Latin America is estimated to exceed $450,000 USD. In a country like Mexico, where the minimum daily wage is approximately $10 USD, access to these therapies remains unattainable for the majority of the population. Therefore, it is essential to highlight the importance and substantial clinical impact of immunotherapy on survival outcomes in patients with refractory neuroblastoma. This recognition should support advocacy for broader access to these therapies. Despite their high costs, the demonstrated benefits should outweigh the disadvantages, justifying efforts to make them accessible to all patient populations.Future studies in LMICs including Mexico and Latin America, must focus on optimizing dosing strategies to minimize adverse effects and improve both survival outcomes and the quality of life for patients receiving immunotherapy.
Keywords: Neuroblastoma High Risk, Inmunotherapy, naxitamab, Latin America, pediatric cancer
Received: 30 Oct 2024; Accepted: 23 May 2025.
Copyright: © 2025 Olaya Vargas, Salazar-Rosales, Caballero-Palacios, Ramírez-Uribe, López-Hernández, Morales-Martinez, Cervantes-Delgado, Velasco Hidalgo, Castellanos-Toledo, Cárdenas-Cardos, Niembro-Zúñiga, Rivera-Luna, Olaya-Nieto, Ponce-Cruz, Shalkow, Melchor-Vidal and Díaz-Machorro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Alberto Olaya Vargas, Department of Hematopoietic Transplantation and Cellular Therapy, National Institute of Pediatrics (Mexico), Mexico City, Mexico
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.